15197:2013, accuracy criteria define a BGMS to be accurate if ≥95% of results fall within ±15 mg/dL of a reference laboratory result when blood glucose concentrations are <100 mg/dL or within ±15% of the reference when blood glucose concentrations are ≥100 mg/dL. 10 An updated FDA guidance published in October 2016 recommended that 95% of all BGMS results should be within ±15%, and 99% of all BGMS results should be within ±20% of the reference laboratory method across the entire claimed measuring range of the BGMS. 9 These more stringent guidelines recognized the limitations of evaluating blood glucose samples at the extreme ends of the measuring range, especially in the low range where very few samples are available. Recognizing the clinical importance of the accuracy of blood glucose measurements for hypo-and hyperglycemic blood samples, both European and US authorities have requested that accuracy data be reported separately for low, normal, and high blood glucose ranges. 9, 10 Although ISO standards continue to improve over time, a need remains to evaluate analytical performance in the critically important hypoglycemic range, since performance in detecting low blood glucose levels is important for the detection and management of hypoglycemia. The current investigation was undertaken to assess a new methodology to allow a closer examination of BGMS accuracy. This evaluation assessed performance and identified subtle differences between BGMSs not only in different blood glucose ranges but also at specific blood glucose concentrations across the entire range.
Methods

Simulated Blood Glucose Monitor Sensitivity Analyses
The methodology we have developed was applied to sensitivity analyses based on simulated BGMS data. Three individual BGMSs were simulated: an "underperforming" unit (BGMS I), an adequately performing unit (BGMS II), and an "overperforming" unit (BGMS III). These simulated BGMS data sets were used to provide outputs across 3 ranges of blood glucose concentrations based on recently published recommendations for the use of ambulatory blood glucose profiles in clinical practice: low (30-70 mg/dL), normal (70-180 mg/dL), and high (180-600 mg/dL) blood glucose concentrations. 11 The parameters used to simulate each BGMS were as follows: BGMS I, intercept = -5.00 (β 0 ), slope = 0.950 (β 1 ), CV = 6% (100%c); BGMS II, intercept = 5.00, slope = 1.020, CV = 4%; BGMS III, intercept = 1.50, slope = 1.040, CV = 3% (Table 1) . A sample of N = 1000 laboratory method results (comparator) were simulated from a gamma distribution having shape parameter = 4.4 and scale parameter = 36.8. The primary outputs were probabilities that each meter would yield an error (100%r) of ±5%, ±10%, ±15%, and ±20% over multiple specific blood glucose values within each blood glucose range based on aggregate statistics (ie, not for specific blood glucose values). The probability that percentage relative error, RD, falls within ±100%r was computed using the equations, together with the standard normal distribution: 
Real-World Blood Glucose Monitor Sensitivity Analyses
To investigate the sensitivities of BGMSs used in practice, actual clinical blood glucose data from a previous study that compared the accuracy of multiple BGMSs were used; these blood glucose data were obtained from capillary fingertip blood. 12, 13 Using these results, regression models were fit to blood glucose data and graphed with BGMS results on the y-axis and reference blood glucose results on the x-axis. Three different real-world BGMSs were assessed, anonymized as "BGMS A," "BGMS B," and "BGMS C" (Table 1) . A weighted least squares method was used to account for the proportional nature of standard deviations (ie, the standard deviation was proportional to the laboratory value of the blood glucose concentration). Regression coefficients, together with statistical estimates of coefficients of variation, were used to compute the probability that, for any given blood glucose value, the BGMS result would be within ±15% of the laboratory value, and 95% lower confidence limits on 
Results
Accuracy Probability Curves Using Data From Simulated BGMSs
To establish baseline results across prespecified conditions, we created probability curves across a range of blood glucose levels, accuracy criteria, and BGMS performance capabilities. Three ranges of blood glucose levels were imputed; specifically, low (30-70 mg/dL), normal (70-180 mg/dL), and high (180-600 mg/dL), based on recently published recommendations. 11 For each of these ranges, 3 simulated BGMSs were modeled: an "underperforming" unit (BGMS I), an "adequately" performing unit (BGMS II), and an "overperforming" unit (BGMS III). Table 2 shows the resulting probabilities of each simulated BGMS achieving accuracy within ±5%, ±10%, ±15%, and ±20% of laboratory derived values across the specified ranges of blood glucose levels. These results provide the expected outcomes for an underperforming unit (BGMS I; Figure 1A ), which would not meet EN ISO 15197:2015 (ISO 15197:2013) requirements; an adequately performing unit (BGMS II; Figure 1B ), which would achieve EN ISO 15197:2015 (ISO 15197:2013) requirements; and an overperforming unit (BGMS III; Figure  1C ), which would exceed EN ISO 15197:2015 (ISO 15197:2013) requirements. In addition, the proportions of results within specified error rates compared with laboratory reference values for each simulated BGMS and blood glucose range are presented in Table 2 .
Accuracy Probability Curves Using Data From Real-World BGMSs
Using results from actual capillary fingertip blood glucose samples, accuracy probability curves and 95% lower confidence limits were generated for 3 different real-world BGMSs, anonymized as BGMS A, BGMS B, and BGMS C. 
Accuracy at Specific Blood Glucose Levels in Lower, Normal, and Higher Blood Glucose Ranges
We also assessed the proportion of blood glucose measurements that fall within 95% and 99% ranges at different specified blood glucose levels. Results for the 3 real-world BGMSs are summarized for the following blood glucose levels: 54.0 mg/dL (low) is summarized in Table 3 ; 72.1, 90.1, 126.1, and 162.1 mg/dL (normal) are summarized in Table 4 ; and 270.2, 405.4, and 540.5 mg/dL (high) are summarized in Table 5 
Discussion
The accuracy of BGMSs is clearly associated with risk of hypoglycemic events, 14 and the incidence of hypoglycemia may rise progressively as the magnitude of BGMS error increases. 15 If BGMS values are too high, users may overcorrect with increased insulin administration, resulting in hypoglycemia. In contrast, if BGMS results are too low, users may increase intake of readily absorbable carbohydrates to raise blood glucose, which may result in hyperglycemia and subsequent increases in HbA1c. 14 In addition, for people with diabetes who are treated by insulin and/or use insulin pumps, inaccurate glucose readings could lead to erroneous insulin dose calculations. Because of the dangers associated with hypoglycemia, 2 prevention of hypoglycemia is a primary concern for people with diabetes; therefore, accuracy requirements for BGMSs in the hypoglycemic range should be particularly stringent. 16 The least biased (or most accurate) blood glucose readings would support achievement of the lowest possible HbA1c and the least possible hypoglycemia, 17 which is an important goal of modern diabetes treatment and technologies. Current requirements for SMBG device accuracy, namely ISO 15197:2013, EN ISO 15197:2015, and the FDA 2016 criteria, do not guarantee stringency (eg, a 95% probability of obtaining an accurate result at a specific blood glucose concentration). The methodology proposed in the current study helps address these potential gaps and implications for diabetes management.
Results of our study demonstrated that, using a linear model of BGMS measurements as a function of laboratory results, curves can be generated to provide the estimated Figure 1 . Curves showing probabilities of simulated BGMSs achieving accuracy within ±5%, ±10%, ±15%, and ±20% error rates compared with laboratory-derived values at low, normal, and high blood glucose ranges and of achieving ±15% accuracy across all ranges with (A) BGMS I (underperforming), (B) BGMS II (adequately performing), and (C) BGMS III (overperforming).
probability of a blood glucose value falling within any particular bounds at any blood glucose concentration within a specified range. The probability curves we generated showed that all 3 real-world BGMSs tested met EN ISO 15197:2015 (ISO 15197:2013) accuracy criteria and 95% lower confidence limits. Based on potential clinical implications of poor glycemic control, 2 we also examined the quality of blood glucose measurements in the hypoglycemic, euglycemic, and hyperglycemic ranges. 16 To that end, although all 3 realworld BGMSs met accuracy criteria, variability between BGMSs was identified in the low blood glucose range, as 2 BGMSs showed decreased accuracy when blood glucose levels were <70 mg/dL, and 1 BGMS showed noticeably reduced accuracy at blood glucose values <50 mg/dL. Such information about variabilities in BGMS accuracy is particularly useful, since small errors can have substantial consequences for patient-related outcomes-particularly where errors in the low blood glucose range can increase the risk of hypoglycemia and related sequelae.
It is important to note that the methodology reported here is not simulation based. It is a computational methodology that can be applied to any BGMS data set. In this paper, we demonstrate the application of this method to data from simulated BGMSs as well as actual clinical data from real-world BGMSs to illustrate how the method might elucidate error characteristics of various meters. In addition, our methodology does not modify the data set in any way; rather, it analyzes the data set to obtain additional information on BGMS performance. Our methodology allows one to better understand heterogeneity in sets of blood glucose data that already meet any analytical performance standard, such as the standards provided by ISO. This methodology can be used to expand our understanding of the data beyond the minimum threshold that passing a standard implies.
This article reflects a new approach to the analysis of populations of actual or simulated BGMS data. It is not an evaluation of any particular BGMS. In addition, assumptions were made to construct the probability curves, including normality of (signed) relative (percentage) difference, which is only an approximation/model.
Conclusions
Probability curves highlight the importance of BGMS accuracy at any given blood glucose concentration across the entire blood glucose range to achieve optimal glycemic control while avoiding hypoglycemia or hyperglycemia. Such curves can be used to elucidate potential ranges of blood glucose concentrations and reveal when BGMSs may not be as accurate as desired, even when aggregate EN ISO 15197:2015 (ISO 15197:2013) and/or FDA criteria are satisfied. This information may be especially significant in low blood glucose ranges where small errors in BGMS measurements can have substantial impacts on patient-related outcomes, including hypoglycemia risk. 
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